Publications by authors named "Matts Kagedal"

Claim this Profile
S
Simulation-based evaluation of personalized dosing approaches for anti-FGFR/KLB bispecific antibody fazpilodemab.
Kenta Yoshida, Victor Poon, Ajit Dash, Rebecca Kunder, Leslie Chinn

CPT Pharmacometrics Syst Pharmacol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
gPKPDviz: A flexible R shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve.
Tong Lu, Victor Poon, Logan Brooks, Erick Velasquez, Eric Anderson

CPT Pharmacometrics Syst Pharmacol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration.
Matts Kågedal, Oskar Alskär, Klas Petersson, Eva Hanze, Mauricio Maia

J Clin Pharmacol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score.
Anita Moein, Jurgen Langenhorst, Elodie L Plan, Jin Y Jin, Matts Kågedal

Clin Transl Sci· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Support to early clinical decisions in drug development and personalised medicine with checkpoint inhibitors using dynamic biomarker-overall survival models.
René Bruno, Pascal Chanu, Matts Kågedal, Francois Mercier, Kenta Yoshida

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration.
Charles C Wykoff, Peter A Campochiaro, Dante J Pieramici, Arshad M Khanani, Shamika Gune

Ophthalmol Ther· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of pharmacokinetic linearity after repeated drug administration.
Alexander Bauer, Matts Kagedal, Martin J Wolfsegger

Pharm Stat· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk

Cancer Chemother Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A longitudinal model for the Mayo Clinical Score and its sub-components in patients with ulcerative colitis.
Sonoko Kawakatsu, Rui Zhu, Wenhui Zhang, Meina T Tang, Tong Lu

J Pharmacokinet Pharmacodyn· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Michael Z Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk

Cancer Chemother Pharmacol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confounding factors in exposure-response analyses and mitigation strategies for monoclonal antibodies in oncology.
Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish

Br J Clin Pharmacol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy.
Eric Reyner, Bert Lum, Jing Jing, Matts Kagedal, Joseph A Ware

Clin Transl Sci· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics.
Jiajie Yu, Nina Wang, Matts Kågedal

CPT Pharmacometrics Syst Pharmacol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.
Tong Lu, Yujie Yang, Jin Y Jin, Matts Kågedal

CPT Pharmacometrics Syst Pharmacol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates.
Matts Kågedal, Divya Samineni, William R Gillespie, Dan Lu, Bernard M Fine

CPT Pharmacometrics Syst Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study.
Whitney P Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott

Cancer Chemother Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study.
Whitney P Kirschbrown, Chris Wynne, Matts Kågedal, Russ Wada, Hanbin Li

J Clin Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Shang-Chiung Chen, Matts Kagedal, Yuying Gao, Bei Wang, Marie-Laurence Harle-Yge

Cancer Chemother Pharmacol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni

J Pharmacokinet Pharmacodyn· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC).
Shang-Chiung Chen, Matts Kagedal, Yuying Gao, Bei Wang, Marie-Laurence Harle-Yge

Cancer Chemother Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue model.
Matts Kågedal, Katarina Varnäs, Andrew C Hooker, Mats O Karlsson

Br J Clin Pharmacol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment.
Matts Kågedal, Mats O Karlsson, Andrew C Hooker

J Pharmacokinet Pharmacodyn· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, Paul Martin, Eugène Cox

J Clin Pharmacol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR.
Svante Nyberg, Aurelija Jucaite, Akihiro Takano, Matts Kågedal, Zsolt Cselényi

Int J Neuropsychopharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis